Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Industry Overview - The fourth-quarter 2024 earnings season for the Medical sector is currently underway, primarily involving pharma/biotech and medical device companies [1] - As of February 12, 72.1% of companies in the Medical sector, representing 91.4% of the sector's market capitalization, reported quarterly earnings, with 81.8% surpassing earnings estimates and 79.5% beating revenue estimates [2] - Year-over-year, earnings in the Medical sector increased by 16.9%, while revenues rose by 10.1% [2] - Overall, fourth-quarter earnings are expected to increase by 13.4%, with sales projected to rise by 9.6% compared to the previous year [2] Company Performances Axsome Therapeutics (AXSM) - Axsome has a strong earnings track record, beating estimates in each of the last four quarters with an average earnings surprise of 14.09% [4] - For the upcoming quarter, Axsome has an Earnings ESP of -7.22% and a Zacks Rank 3, with a consensus estimate for a loss per share of $1 [6] - Revenue growth is anticipated from strong sales of its products Auvelity and Sunosi, along with an update on the commercialization plans for the newly FDA-approved Symbravo [7][8] Halozyme Therapeutics (HALO) - Halozyme has a mixed earnings surprise history, beating estimates in three of the last four quarters with an average surprise of 14.86$1.16 [10] - Revenue is expected to be driven by higher royalty payments from Roche and JNJ, along with increased collaboration revenues and sales of its proprietary products [11][12] Amicus Therapeutics (FOLD) - Amicus has a mixed earnings track record, beating estimates in three of the last four quarters with an average surprise of 27.09% [13] - The company has an Earnings ESP of -16.67% and a Zacks Rank 3, with a consensus estimate for earnings per share at 10 cents [14] - Revenue growth is likely driven by strong demand for its Fabry disease drug, Galafold, and sales from its Pompe disease combo drug [14][15] BioMarin Pharmaceutical (BMRN) - BioMarin has an impeccable earnings track record, beating estimates in each of the last four quarters with an average surprise of 28.7% [16] - The company has an Earnings ESP of -1.48% and a Zacks Rank 2, with a consensus estimate for earnings per share at 73 cents [16] - Sales of its achondroplasia drug, Voxzogo, are expected to be the primary revenue contributor, along with increased sales of other marketed products [17][18] Insmed (INSM) - Insmed has a disappointing earnings track record, beating estimates only once in the last four quarters with an average negative surprise of 16.48% [18] - The company has an Earnings ESP of +1.62% and a Zacks Rank 3, with a consensus estimate for a loss per share of $1.15 [19] - Revenue is expected to be driven by sales of its only marketed drug, Arikayce, which has seen continued growth in demand [20]